Merck (MRK) Declares $0.45 Quarterly Dividend; 3.1% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Stocks fall as higher oil prices, Treasury yields weigh
Merck Announces Third-Quarter 2015 Dividend
May 26, 2015 1:31 PM EDTKENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.45 per share of the companys common stock for the third quarter of 2015. Payment will be made on July 8, 2015, to stockholders of record at the close of business on June 15, 2015.
About Merck
Todays Merck is a global health care leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription... More
SIMPONI® (golimumab) Gains Positive Opinion from Committee for Medicinal Products for Human Use (CHMP) for the Treatment of Non-Radiographic Axial Spondyloarthritis
May 26, 2015 6:34 AM EDTKENILWORTH, New Jersey, May 26, 2015 /PRNewswire/ --
MSD, known as Merck & Co., Inc. in the United States and Canada,- today announced that SIMPONI®(golimumab) has received CHMP positive opinion for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).[1] Once the EU commission issues their EC decision, and if approved, nr-axial SpA patients can be considered for the... More
